Antibodies to amyloid beta

Patent metadata

Field	Value
Publication number	US-9834598-B2
Application number	US-201314435520-A
Country	US
Kind code	B2
Filing date	Oct 15, 2013
Priority date	Oct 15, 2012
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

First claim

What is claimed is:

1. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40), wherein the antibody molecule comprises (i) a VH domain comprising the Abet0380 set of HCDRs, wherein the amino acid sequences of the Abet0380 HCDRs are
HCDR1 SEQ ID NO: 525,
HCDR2 SEQ ID NO: 526, and
HCDR3 SEQ ID NO: 527,

or comprising the Abet0380 set of HCDRs with one or two amino acid mutations, and (ii) a VL domain comprising the Abet0380 set of LCDRs, wherein the amino acid sequences of the Abet0380 LCDRs are
LCDR1 SEQ ID NO: 534
LCDR2 SEQ ID NO: 535, and
LCDR3 SEQ ID NO: 536,

or comprising the Abet0380 set of LCDRs with one or two amino acid mutations.

2. An antibody molecule according to claim 1 , comprising the Abet0380-GL VH domain amino acid sequence SEQ ID NO: 524 and the Abet0380-GL VL domain amino acid sequence SEQ ID NO: 533.

3. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40) that competes for binding to Aβ1-42 with an antibody molecule comprising a VH domain amino acid sequence SEQ ID NO: 524 and a VL domain amino acid sequence SEQ ID NO: 533.

4. A composition comprising an antibody molecule according to claim 1 , and a pharmaceutically acceptable excipient.

5. A method of treating a human or animal subject having an amyloidosis associated with amyloid beta, the method comprising administering to the subject the antibody of claim 1 .

6. The method according to claim 5 , wherein the treatment at least reduces amyloidosis; treats Alzheimer's disease; improves cognition or reduces cognitive decline in an Alzheimer's disease or Down's syndrome patient; or treats macular degeneration.

7. A method of at least reducing amyloidosis, treating Alzheimer's disease, improving cognition or reducing cognitive decline in an Alzheimer's disease or Down's syndrome patient, and/or treating macular degeneration in an individual, comprising administering to the individual an antibody molecule according to claim 1 .

Assignees

• Medimmune Ltd

Inventors

• Groves Maria
• Gustavsson Suzanne
• Höglund Kina
• Lloyd Chris
• Nickson Adrian
• Niva Camilla
• Simon Sylvia
• Lowne David
• Welsh Fraser
• Freskgärd Per-Ola

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/567

  Framework region [FR] · CPC title